Haimovitz Jules 4

What Happened Jules Haimovitz, a director of Armata Pharmaceuticals, was granted a derivative award of 25,640 shares on March 9, 2026. The Form 4 records the acquisition price as $0.00 (standard reporting for option or award grants); no cash was exchanged at grant. This was an award/grant (code A), not a purchase or sale of outstanding shares.

Key Details

• Transaction date: 2026-03-09; Form 4 filed: 2026-03-11 (timely filing).
• Reported amount: 25,640 shares (derivative award) at $0.00 reported price.
• Shares owned after transaction: not specified in the information provided in this summary.
• Footnote: The options “will vest in full on March 9, 2027,” subject to continued service through the vesting date.
• Transaction type: Award/Grant of derivative securities (not an immediate exercise or sale).

Context This grant represents a future right to acquire shares (typically stock options or restricted stock units) that must vest before becoming exercisable or convertible into common stock. It does not represent newly issued common shares outstanding until vested/exercised and therefore is different from an outright purchase or sale. Awards to directors are a common form of compensation and should be interpreted as part of compensation arrangements rather than a direct market buy/sell signal.